HistoRx licenses new melanoma assay from Yale
HistoRx Inc. (cancer diagnostics) has licensed a new prognostic melanoma assay from Yale University. (Dec.)
Recent Tech Transfer Deals (01/2012)
Our monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions--in the fields of life sciences, including in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical devices.
More from Deals
More from Business
• By
Lilly’s Mounjaro for diabetes rose from sixth to third position among the top-selling drugs in the first quarter of 2025, Rival Ozempic retained second position and Merck & Co’s immuno-oncology blockbuster Keytruda stayed far ahead.
• By
Oral RNA splicing modulator has gone into a Phase II/III trial
BIO Notebook: MFN Pricing, Next-Gen Obesity R&D, FDA’s Rare Disease Hub & Reaction To Review Program
• By
Highlights from Day 3 of the BIO International Convention include the realities of MFN pricing, AstraZeneca's R&D plans for obesity, the need for resources for FDA's rare disease hub and reactions to the Commissioner's National Priority Review Voucher program.